Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivekimab sunirine alone or with venetoclax and/or azacitidine in CD123-positive acute myeloid leukemia
2024-514197-50-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of pivekimab sunirine, venetoclax and azacitidine in acute myeloid leukemia (AML) (4 arms), sponsored by AbbVie Inc. Planned start Jan 2020; status: authorised.
02
Drugs
pivekimab sunirinevenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-514197-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514197-50-00.